LATEST NEWS

Category Archives: Fispemifene

Fispemifene program focus returning to LUTS (lower urinary tract symptoms)

Our US development and licensing partner, Apricus Biosciences Inc., yesterday announced (link to press release) their phase 2b results of Fispemifene for the treatment of sexual dysfunction in men with secondary hypogonadism. Although the testosterone levels were significantly elevated, the symptomatic endpoints were not met in this study population. Fispemifene was well tolerated by the […]

Meet us in Stockholm during Bio-Europe Spring

Forendo Pharma will participate in the BIO-Europe Spring® partnering conference in Stockholm, Sweden, during April 4th to 6th 2016. We will be meeting with potential licensing partners for our Fispemifene program. In order to schedule a meeting with us, please use the conference PartneringONE system or send us a message: businesscontacts@forendo.com We look forward to seeing […]

Meet us in San Francisco during Biotech Showcase 2016

Forendo Pharma will be in San Francisco, California, for meetings with partners during Biotech Showcase and JP Morgan conference, from January 11th to 13th 2016. Biotech Showcase is the leading investor conference for mid-small cap and private biotech and life science companies. Our company presentation will be on Monday, January 11th, at 3:30 pm. Please contact […]

Press Release: Fispemifene US development and commercialization rights licensed to Apricus Biosciences Inc.

Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men Turku, Finland, October 20th, 2014. Forendo Pharma Oy announced today that it has entered into a definitive agreement to out-license the US development and commercialization rights for fispemifene to Apricus Biosciences Inc. Fispemifene is a selective estrogen modulator (SERM), […]